Journal of Medicinal Chemistry
BRIEF ARTICLE
All reactions were monitored by TLC performed on silica gel plates
0.2 mm thick (60 F254 Merck); spots were visualized by UV light.
Melting points were uncorrected and were determined on a Stuart
SMP11 melting point apparatus (Table S1, Supporting Information).
1H NMR spectra were recorded on a Bruker AMX (300 MHz) or a
Varian Unity 600 (600 MHz); deuterated chloroform (CDCl3) was used
as solvent. Chemical shifts are expressed as δ units (parts per million)
using TMS as an internal standard. Coupling constants J are in hertz
(Hz) (Supporting Information). Electron ionization (EI) mass spectra
were obtained using a Fisons QMD 1000 mass spectrometer (70 eV,
200 μA, ion source temperature of 200 ꢀC). The samples were intro-
duced directly into the ion source. Elemental analysis results for C, H,
and N were recorded on a Perkin-Elmer 240 B microanalyzer and were
within (0.4% of the theoretical values for all compounds.
(7) Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.;
Befani, O.; Turini, P.; Giovannini, V.; Mondovi, B.; Cirilli, R.; La Torre,
ꢀ
F. Synthesis and Selective Inhibitory Activity of 1-Acetyl-3,5-diphenyl-
4,5-dihydro-(1H)-pyrazole Derivatives against Monoamine Oxidase.
J. Med. Chem. 2004, 47, 2071–2074.
(8) Chimenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.;
Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F.; Cirilli, R.; La Torre,
F.; Cardia, M. C.; Distinto, S. Synthesis, Molecular Modeling Studies, and
Selective Inhibitory Activity against Monoamine Oxidase of 1-Thiocarba-
moyl-3,5-diaryl-4,5-dihydro-(1H)-pyrazole Derivatives. J. Med. Chem. 2005,
48, 7113–7122.
(9) Maccioni, E.; Alcaro, S.; Orallo, F.; Cardia, M. C.; Distinto, S.;
Costa, G.; Yanez, M.; Sanna, M. L.; Vigo, S.; Meleddu, R.; Secci, D.
Synthesis of New 3-Aryl-4,5-dihydropyrazole-1-carbothioamide Deriva-
tives. An Investigation on Their Ability To Inhibit Monoamine Oxidase.
Eur. J. Med. Chem. 2010, 45, 4490–4498.
’ ASSOCIATED CONTENT
(10) Mazouz, F.; Gueddari, S.; Burstein, C.; Mansuy, D.; Milcent, R.
5-[4-(Benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one Derivatives and
Related Analogs: New Reversible, Highly Potent, and Selective Mono-
amine Oxidase Type B Inhibitors. J. Med. Chem. 1993, 36, 1157–1167.
(11) Mamolo, M. G.; Zampieri, D.; Vio, L.; Fermeglia, M.; Ferrone,
M.; Pricl, S.; Scialino, G.; Banfi, E. Antimycobacterial Activity of New
3-Substituted 5-(Pyridin-4-yl)-3H-1,3,4-oxadiazol-2-one and 2-Thione
Derivatives. Preliminary Molecular Modeling Investigations. Bioorg.
Med. Chem. 2005, 13, 3797–3809.
(12) Bakht, M. A.; Yar, M. S.; Abdel-Hamid, S. G.; Al Qasoumi, S. I.;
Samad, A. Molecular Properties Prediction, Synthesis and Antimicrobial
Activity of Some Newer Oxadiazole Derivatives. Eur. J. Med. Chem.
2010, 45, 5862–5869.
(13) Johns, B. A.; Weatherhead, J. G.; Allen, S. H.; Thompson, J. B.;
Garvey, E. P.; Foster, S. A.; Jeffrey, J. L.; Miller, W. H. 1,3,4-Oxadiazole
Substituted Naphthyridines as HIV-1 Integrase Inhibitors. Part 2: SAR
of the C5 Position. Bioorg. Med. Chem. Lett. 2009, 19, 1807–1810.
(14) Manjunatha, K.; Poojary, B.; Lobo, P. L.; Fernandes, J.; Kumari,
N. S. Synthesis and Biological Evaluation of Some 1,3,4-Oxadiazole
Derivatives. Eur. J. Med. Chem. 2010, 45, 5225–5233.
(15) Rollas, S.; Gulerman, N.; Erdeniz, H. Synthesis and Antimicro-
bial Activity of Some New Hydrazones of 4-Fluorobenzoic Acid
Hydrazide and 3-Acetyl-2,5-disubstituted-1,3,4-oxadiazolines. Farmaco
2002, 57, 171–174.
S
Supporting Information. Chemicalꢀphysical properties
b
1
of 1,3,4-oxadiazoles, H NMR spectra, enantioselective HPLC
chromatograms, enantiomeric purity and specific rotations of the
first and second eluted enantiomers, absolute configuration
assignment by CD correlation, biological assay and molecular
modeling details, GRID maps, MD analysis. This material is
’ AUTHOR INFORMATION
Corresponding Author
*Phone: +39 0961 3694197. Fax: +39 0961 391490. E-mail:
’ ACKNOWLEDGMENT
The work was supported by Fondazione Banco di Sardegna.
The authors thank Roberto Maxia for technical support.
’ ABBREVIATIONS USED
(16) Hearn, M. J.; Chanyaputhipong, P. Y. Preparation and Spectro-
scopic Properties of 3-Acyl-1,3,4-oxadiazolines. J. Heterocycl. Chem. 1995,
32, 1647–1649.
(17) Sanna, M. L.; Maccioni, E.; Vigo, S.; Faggi, C.; Cirilli, R.
Application of an Immobilised Amylose-Based Chiral Stationary Phase
to the Development of New Monoamine Oxidase B Inhibitors. Talanta
2010, 82, 426–431.
MAO, monoamine oxidase; PD, Parkinson’s disease; CD, circu-
lar dichroism; HPLC, high-performance liquid chromatography;
TLC, thin layer chromatography; FAD, flavin adenine dinucleo-
tide; vdW, van der Waals; EWD, electron-withdrawing; HB,
hydrogen bond; MD, molecular dynamics
(18) Yꢁa~nez, M.; Fraiz, N.; Cano, E.; Orallo, F. Inhibitory Effects of
Cis- and Trans-Resveratrol on Noradrenaline and 5-Hydroxytryptamine
Uptake and on Monoamine Oxidase Activity. Biochem. Biophys. Res.
Commun. 2006, 344, 688–695.
(19) Schr€odinger Suite; Schr€odinger, LLC: New York, 2009
(20) Edmondson, D. E.; Binda, C.; Mattevi, A. Structural Insights
into the Mechanism of Amine Oxidation by Monoamine Oxidases A and
B. Arch. Biochem. Biophys. 2007, 464, 269–276.
(21) Li, M.; Binda, C.; Mattevi, A.; Edmondson, D. E. Functional
Role of the “Aromatic Cage” in Human Monoamine Oxidase B:
Structures and Catalytic Properties of Tyr435 Mutant Proteins. Bio-
chemistry 2006, 45, 4775–4784.
(22) Hunter, C. A. Meldola Lecture. The Role of Aromatic Interac-
tions in Molecular Recognition. Chem. Soc. Rev. 1994, 23, 101–109.
(23) GRID, version 22; Molecular Discovery Ltd.: Pinner, Middlesex,
U.K.
’ REFERENCES
(1) Youdim, M. B. H.; Edmondson, D.; Tipton, K. F. The Ther-
apeutic Potential of Monoamine Oxidase Inhibitors. Nat. Rev. Neurosci.
2006, 7, 295–309.
(2) Elmer, L. W.; Bertoni, J. M. The Increasing Role of Monoamine
Oxidase Type B Inhibitors in Parkinson’s Disease Therapy. Expert Opin.
Pharmacother. 2008, 9, 2759–2772.
(3) Saura, J.; Luque, J. M.; Cesura, A. M.; Da Prada, M.; Chan-Palay,
V.; Huber, G.; Loffler, J.; Richards, J. G. Increased Monoamine Oxidase
B Activity in Plaque-Associated Astrocytes of Alzheimer Brains Revealed
by Quantitative Enzyme Radioautography. Neuroscience 1994, 62,
15–30.
(4) Kumar, M. J.; Nicholls, D. G.; Andersen, J. K. Oxidative {alpha}-
Ketoglutarate Dehydrogenase Inhibition via Subtle Elevations in Mono-
amine Oxidase B Levels Results in Loss of Spare Respiratory Capacity:
Implications for Parkinson’s Disease. J. Biol. Chem. 2003, 278, 46432–46439.
(5) Chen, J. J.; Swope, D. M.; Dashtipour, K. Comprehensive Review
of Rasagiline, a Second-Generation Monoamine Oxidase Inhibitor, for
the Treatment of Parkinson’s Disease. Clin. Ther. 2007, 29, 1825–1849.
(6) Fariello, R. G. Safinamide. Neurotherapeutics 2007, 4, 110–116.
6398
dx.doi.org/10.1021/jm2002876 |J. Med. Chem. 2011, 54, 6394–6398